Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 5NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Burkitt Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1

Interventions

Vincristine 17Cyclophosphamide 17Cytarabine 16Methotrexate 14Doxorubicin 14Prednisone 11Etoposide 11Radiotherapy 10merphos 9Rituximab 8Dexamethasone 8pegaspargase 7Leucovorin 7Filgrastim 7Calcium Dobesilate 7Methylprednisolone 6Daunorubicin 6dexamethasone acetate 5dexamethasone 21-phosphate 5calaspargase pegol 5azathiopurine 5auricularum 5Thioguanine 5Mercaptopurine 5Hydrocortisone 5Granulocyte Colony-Stimulating Factor 5Asparaginase 5prednylidene 4deltacortene 4Specimen Handling 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Burkitt Lymphoma × ibritumomab tiuxetan × Clear all
NCT00070018 2022-01-11

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

SWOG Cancer Research Network

Phase 2 Completed
46 enrolled 5 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell

NCT00310128 2016-02-03

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

AIDS Malignancy Consortium

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡